Indivior slumps after profit warning, drug discontinuation - Indivior stock slumped Tuesday after the U.K. pharmaceutical company issued a 2024 profit warning, and announced that it was discontinuing the sales of its schizophrenia drug Perseris.

At 07:00 ET (11:00 GMT), Indivior shares fell over 36% to 751.25p, to its lowest price this year. 

Indivior cited unfavorable market conditions impacting its top-selling opioid addiction treatment, with the Sublocade drug facing intense competition from the launch of a rival, as well as the end of pandemic-relief measures that has led to loss of coverage in the United States for some people enrolled in government-backed Medicaid plans.

The drugmaker said it now expects to generate $1.150-$1.215 billion in revenues for 2024, down from earlier guidance of $1.240-$1.330 billion, with adjusted operating profits penciled in at $285-$320 million, compared with previous projections of $330-$380 million.

Indivior also said it was taking "decisive action that we believe is in the best interest of shareholders" by discontinuing sales of Perseris.

However, “longer term, Indivior still expects to exit 2025 at a $1bn net revenue run-rate and achieve peak sales >$1.5b,” Jefferies said.

The investment bank maintained a ‘buy’ rating on Indivior, with a 2,390p price target.


Begin trading today! Create an account by completing our form

Privacy Notice

At One Financial Markets we are committed to safeguarding your privacy.

Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.

Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.

Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.

By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68.5% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Back to top

Office network

One Financial Markets is the trading name of Axi Financial Services (UK) Ltd, a company registered in England with company number 6050593. Axi Financial Services (UK) Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201) and the Financial Sector Conduct Authority in South Africa (with FSP number 45784).

The information on this site is not directed at residents of the United States, Belgium, Poland or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. is owned and operated by Axi Financial Services (UK) Ltd.

Award winning broker
We have been presented with a number of awards that recognise the quality of our service and dedication to our clients :

Best FSA Regulated Broker
Saudi Money Expo

Best Education Product
Saudi Money Expo

Best Broker - Online Trading
IAIR Awards

Best Institutional Broker
Saudi Money Expo

Best FX Services Broker
CN Forex

Top International
FX Broker 2015

Saudi Money Expo

Broker of the Year
Online Trading – Middle East

IAIR Awards

Best Forex
Customer Service 2018

JFEX Awards

We accept the following payment methods: